Potential of rifamides to inhibit TNF-induced NF-kappaB activation.
Rifamides are important components in the treatment of tuberculosis. However, it is well documented that these drugs can have immunosuppressive activity, a property of these drugs that is particularly relevant to AIDS patients. In this study, we have shown that a number of rifamide analogues have the potential to block tumour necrosis factor (TNF)- or phorbol myristate acetate-induced NF-kappaB activation. As TNF is important in the host defence against tuberculosis, suppression of this activity may provide a potential mechanism of rifamide immunosuppressive activity.
Pahlevan
Ali A
AA
Infectious Diseases and Microbiology, Charing Cross Campus, Imperial College, London, UK.
Wright
David J M
DJ
Bradley
Laura
L
Smith
Clive
C
Foxwell
Brian M J
BM
D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D001427:Bacterial Toxins / Q000494:pharmacology; D006801:Humans; D019169:Jurkat Cells; D019911:Mycobacterium ulcerans / Q000254:growth & development; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000235:genetics; D012293:Rifampin / Q000031:analogs & derivatives / Q000494:pharmacology*; D015533:Transcriptional Activation; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D000904:Antibiotics, Antitubercular; D001427:Bacterial Toxins; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D012293:Rifampin